Showing results (361-370 of 501) with videos related to

Sort By:
Pageof 51
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2019
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 TrialSeth A Rosenthal, Chen Hu, Oliver Sartor, et al.
The Lancet. Oncology|October 17, 2016
Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysisShuang G Zhao, S Laura Chang, Daniel E Spratt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2020
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate CancerXiangnan Guan, Duanchen Sun, Eric Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2024
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP InhibitorsJonathan Chou, Troy M Robinson, Emily A Egusa, et al.
JCO Precision Oncology|October 24, 2024
Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital HistopathologyJonathan David Tward, Huei-Chung Huang, Andre Esteva, et al.
Genome Biology|April 16, 2026
Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancerThaidy Moreno-Rodriguez, Meng Zhang, Arian Lundberg, et al.
Biorxiv : the Preprint Server for Biology|September 16, 2024
Cis-Regulatory Element and Transcription Factor Circuitry Required for Cell-Type Specific Expression of FOXP3Jennifer M Umhoefer, Maya M Arce, Sean Whalen, et al.
Journal of the National Cancer Institute|October 16, 2018
The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic TargetShuang G Zhao, Jonathan Lehrer, S Laura Chang, et al.
Cancer Research|September 17, 2017
LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer ProgressionYi Liang, Musaddeque Ahmed, Haiyang Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2017
TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer SubgroupDavid P Labbé, Christopher J Sweeney, Myles Brown, et al.
Pageof 51